BPC-157’s legal status has changed more in 2026 than in the previous decade. In February, the US Health Secretary announced a review of restricted peptides. In April, the FDA removed BPC-157 from its Category 2 compounding list. In July, an FDA advisory vote decided if it should be reclassified as Category 1.
Many headlines have created the impression that BPC-157 is now “approved” or “legal for everyone.” Neither is correct. This post will walk through what has changed and what hasn’t in this compound’s regulatory status, and what these changes mean for research labs using the compound.
This article is for informational purposes only. For guidance on your specific circumstances, consult a qualified regulatory attorney.
The short answer
As of September 2026:
• BPC-157 is not an FDA-approved drug
• it is not a legal dietary supplement and cannot be sold for human consumption
• it is no longer on the FDA’s Category 2 (“significant safety concern”) compounding list,
• but it is not yet in Category 1 either. An advisory vote recommended its placement on Category 1, and the FDA rulemaking is still pending
• Research suppliers can sell it for laboratory research use only, clearly labelled as not for human or veterinary use.
What are Category 1 and Category 2?
First, to understand what has changed, you need to understand what these categories are. They come from FDA’s interim lists of bulk drug substances that licensed 503A compounding pharmacies may use. Compounding pharmacies create customized medications for individual patients on the basis of a prescription.
Category 1: substances which pharmacies may compound under the FDA’s evaluation
Category 2: substances the FDA has flagged for significant safety concerns, which pharmacies should not compound
Category 3: substances nominated without enough supporting information to evaluate
These categories apply only to pharmacy compounding, and say nothing about whether a compound is an approved drug, and do not directly regulate the sale of research chemicals to laboratories. This is the source of most of the confusion online.
BPC-157 regulatory timeline
| Date | What happened |
| Jul 23–24, 2026 | FDA’s Pharmacy Compounding Advisory Committee voted 8–6 to recommend adding BPC-157 to Category 1, tied to a proposed ulcerative colitis indication |
| Apr 23, 2026 | BPC-157’s removal from Category 2 was reflected in FDA’s updated compounding information. |
| Apr 15, 2026 | FDA announced the removal of BPC-157 from Category 2 following withdrawal of its nominations. |
| Feb 27, 2026 | HHS Secretary Robert F. Kennedy Jr. announced a broader review involving certain peptides. |
| Sep 2023 | FDA placed BPC-157 in Category 2, citing potential immunogenicity and concerns about peptide-related impurities and API characterization. |
Why BPC-157 was restricted in 2023
When the FDA placed BPC-157 in Category 2 in 2023, it cited two main concerns. The first was immunogenicity, meaning the possibility of the peptide triggering an unwanted immune response. The second was impurities, including peptide-related contaminants that can arise during synthesis. The agency also noted the scarcity of human safety data.
The practical effect was that licensed compounding pharmacies stopped preparing BPC-157. This did not stop the compound from being sold elsewhere. Instead, much of the demand shifted to the research chemical market, which saw a wide range of quality across suppliers.
What the April 2026 change did
On April 15, 2026, the FDA removed BPC-157 and eleven other peptides from Category 2, effective April 23. Basically, this means the FDA no longer lists BPC-157 as a substance with safety risks serious enough to ban compounding.
However, being removed from Category 2 is not the same as being placed on Category 1. Until the FDA formally adds BPC-157 to Category 1, compounding it under Section 503A remains outside the legal exemption, as before its placement on the Category 2 list.
What the July vote does and doesn’t mean
On July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides, including BPC-157 and TB-500. The committee voted 8–6 to recommend adding BPC-157 to the 503A bulk drug substances list.
Three things to know here:
1. Advisory committees advise; the FDA decides. The vote is a recommendation, not a ruling.
2. The vote was narrow and specific. It was tied to a proposed ulcerative colitis indication, and not a general endorsement for all uses.
3. Rulemaking is required. The FDA must complete a formal notice-and-comment process before any pharmacy has clear legal authority to compound BPC-157. Industry estimates suggest this could take 8 to 12 months.
What about TB-500?
TB-500 was part of the same February announcement and same peptide review, and was on the July advisory committee agenda. Like BPC-157, it is not an FDA-approved drug and its compounding status is moving through the same process, so please check the FDA’s bulk drug substances page for the latest update.
Common myths about BPC-157’s legal status
The 2026 news cycle has generated a few common misunderstandings. Here are the most common, and the reality behind each:
| Myth | Reality |
| “BPC-157 is now FDA approved.” | No peptide on the list went through clinical trials or drug approval processes. The changes only concern compounding. |
| “It’s legal to sell as a supplement now.” | BPC-157 is not a lawful dietary supplement and cannot be marketed for human consumption. |
| “Category 1 is already official.” | The July vote was a recommendation; the FDA still has to complete rulemaking. |
| “Research suppliers were illegal before April.” | Compounding lists apply to pharmacies, not to research-only sales to laboratories. |
Keeping these distinctions clear benefits both researchers and suppliers, and explains why reputable research suppliers avoid any human-use language on their product pages or blogs.
Sport and anti-doping
For completeness, BPC-157 is listed by the World Anti-Doping Agency under its S0 category of non-approved substances and remains banned in tested sport regardless of any FDA compounding changes.
What this means for research labs
For laboratory and in-vitro or in-vivo research, practically nothing has changed in the compound landscape. Research peptides remain available for research use where they are:
• labelled and sold for research use only
• not marketed with human dosing, treatment or health claims
• bought by researchers who take responsibility for proper handling
What has changed is attention. The 2026 headlines have generated a wave of new interest, which brings more low-quality sellers. This makes verification more important than ever. Learn how to read a peptide COA and confirm lot-matched HPLC, mass spec and endotoxin data before you order.
For background on the compounds themselves, see BPC-157 vs TB-500: the Wolverine stack explained. Our purchase conditions for research customers are set out in our Terms & Conditions.
FAQ
Is BPC-157 FDA approved in 2026?
No. Leaving Category 2 is not drug approval.
Can a pharmacy compound BPC-157 now?
Not with clear legal authority yet. FDA rulemaking to add it to Category 1 is still pending.
Can I buy BPC-157 for research?
Yes, from suppliers that sell it strictly for laboratory research use, such as Wolverine Peptide.
Could the rules change again?
Yes. The FDA’s final decision on Category 1 could change the picture, so please check for any updates.